

ForPatients

by Roche

Pancreatic Cancer Solid Tumors Malignant Melanoma Renal Cell Carcinoma Cancer Non Hodgkin Lymphoma (NHL) Lymphoma Ovarian Cancer Breast Cancer Thyroid Cancer Melanoma Head and Neck Neoplasms Head and Neck Cancer

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Trial Status
Active, not recruiting

Trial Runs In
16 Countries

Trial Identifier
NCT02568267
2015-003385-84,GO40782
RXDX-101-02

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02568267 2015-003385-84,GO40782 RXDX-101-02
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
